Oral human recombinant epidermal growth factor in the treatment of patients with duodenal ulcer.
The epidermal growth factor has been shown to be mucoprotective and to accelerate healing of gastroduodenal ulcers in animals. A prospective, positively controlled clinical trial was conducted. Seventy five patients with duodenal ulcer were randomly distributed in three groups to receive oral human recombinant epidermal growth factor in 1% carboxymethyl cellulose at two different doses (450 mg or 600 mg/day), or cimetidine. Treatment was administered up to a maximum of 6 weeks. The most important assessment criteria was the proportion of patients healed after 2, 4 and 6 weeks of treatment determined by endoscopy. Treatment with both doses of epidermal growth factor showed a long-term healing effect in 76.5% at 6 weeks vs 92.5% with cimetidine (p = N.S.). The evolution of the clinical symptoms was similar in the three groups. Adverse reactions were not detected in any of the patients included in this study. To our knowledge, this is the first report on the oral use of epidermal growth factor in humans.
Haedo
W
W
National Institute of Gastroenterology, Havana City, Cuba.
González
T
T
Más
J A
JA
Franco
S
S
Gra
B
B
Soto
G
G
Alonso
A
A
López-Saura
P
P
D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000368:Aged; D004381:Duodenal Ulcer / Q000188:drug therapy*; D004815:Epidermal Growth Factor / Q000008:administration & dosage* / Q000096:biosynthesis; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000096:biosynthesis; D013997:Time Factors
D011994:Recombinant Proteins; D004815:Epidermal Growth Factor